{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:37:00Z","timestamp":1790426220556,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>UK guidelines for managing adults with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN), published by the British Association of Dermatologists (BAD) in 2016, outline a set of audit standards.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To audit current management of SJS\/TEN in adults against standards in the BAD guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>BAD members were invited to submit data on five consecutive adults with SJS\/TEN per department over an 8-week period in 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-nine dermatology centres in the UK (29%) participated, and data for 147 adults with SJS\/TEN were collected. Within 24\u2005h of the diagnosis being made or suspected, the following were documented, per 147 submitted cases: Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) for 76 (52%), list of medications for 113 (77%) and timelines for commencement\/alterations of medications for 104 (71%). The initial assessment was documented of the eyes by an ophthalmologist in 71 (48%), of the mouth in 130 (88%), of the genital skin in 103 (70%) and of the urinary tract in 93 (63%). During the first 10\u2005days after a suspected or confirmed diagnosis of SJS\/TEN, daily assessments of the mouth were documented in 26 of 147 cases (18%), of the eyes in 12 (8%), and of the urinary tract and genital skin in 14 (10%). At discharge, a drug was declared to be the cause of SJS\/TEN for 130 of 147 cases (88%), while 9 (6%) were thought to be secondary to infection. Eleven of 147 (8%) had no response to this question. Documentation regarding advice was present on avoidance of the culprit drug in 76 of 130 declared SJS\/TEN cases (58%), and on requesting a MedicAlert\u00ae bracelet\/amulet in 9 of the 147 cases (6%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This audit suggests that a clinical review checklist might be needed to enable colleagues to maintain standards outlined in the guidelines, including documentation of SCORTEN, daily assessments of mucosal areas, and advice to avoid culprit drug(s) and to request a MedicAlert\u00ae bracelet\/amulet.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae010","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T05:32:30Z","timestamp":1705815150000},"page":"810-816","source":"Crossref","is-referenced-by-count":3,"title":["British Association of Dermatologists national clinical audit on the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6746-3865","authenticated-orcid":false,"given":"Fiona","family":"Tasker","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7744-3238","authenticated-orcid":false,"given":"Stephen P","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-0696","authenticated-orcid":false,"given":"M Firouz","family":"Mohd Mustapa","sequence":"additional","affiliation":[{"name":"British Association of Dermatologists , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A R","family":"de Berker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bristol Royal Infirmary , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"2024071909335802700_llae010-B1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981\u20131985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"2024071909335802700_llae010-B2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2024071909335802700_llae010-B3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2024071909335802700_llae010-B4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2024071909335802700_llae010-B5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024071909335802700_llae010-B6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2024071909335802700_llae010-B7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024071909335802700_llae010-B8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2024071909335802700_llae010-B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res"},{"key":"2024071909335802700_llae010-B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"2024071909335802700_llae010-B11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Dermatol"},{"key":"2024071909335802700_llae010-B12","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"2024071909335802700_llae010-B13","author":"Office for National Statistics"},{"key":"2024071909335802700_llae010-B14","volume-title":"Litts Drug Eruption & Reaction Manual","author":"Shear","year":"2023","edition":"29th edn"},{"key":"2024071909335802700_llae010-B15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/pme-2022-0126","article-title":"Genetic predisposition for the development of lamotrigine-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"20","author":"Das","year":"2023","journal-title":"Per Med"},{"key":"2024071909335802700_llae010-B16","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.dmpk.2023.100495","article-title":"Validation of a genotyping technique for a surrogate marker of HLA-B*58:01 for allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in the Japanese population","volume":"49","author":"Tsukagoshi","year":"2023","journal-title":"Drug Metab Pharmacokinet"},{"key":"2024071909335802700_llae010-B17","doi-asserted-by":"crossref","first-page":"607532","DOI":"10.3389\/fgene.2020.607532","article-title":"Genetic markers for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in the Asian Indian population: implications on prevention","volume":"11","author":"Shanbhag","year":"2021","journal-title":"Front Genet"},{"key":"2024071909335802700_llae010-B18","author":"NHS"},{"key":"2024071909335802700_llae010-B19","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071909335802700_llae010-B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology"},{"key":"2024071909335802700_llae010-B21","doi-asserted-by":"crossref","first-page":"649661","DOI":"10.3389\/fmed.2021.649661","article-title":"Findings by an international collaboration on SJS\/TEN with severe ocular complications","volume":"8","author":"Ueta","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024071909335802700_llae010-B22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"2024071909335802700_llae010-B23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024071909335802700_llae010-B24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"2024071909335802700_llae010-B25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaad.2019.08.031","article-title":"Vulvovaginal manifestations in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: prevention and treatment","volume":"85","author":"O\u2019Brien","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024071909335802700_llae010-B26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bjps.2019.07.015","article-title":"Toxic epidermal necrolysis (TEN): acute complications and long-term sequelae management in a multidisciplinary follow-up","volume":"73","author":"Caba\u00f1as Weisz","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2024071909335802700_llae010-B27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00404-009-1008-1","article-title":"Relevance and consequences of erythema multiforme, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in gynecology","volume":"280","author":"Niemeijer","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"2024071909335802700_llae010-B28","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and mortality following severe cutaneous adverse reactions","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"key":"2024071909335802700_llae010-B29","first-page":"e78","article-title":"Recurrence of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in adults","volume":"56","author":"Lee","year":"2017","journal-title":"Int J Dermatol"},{"key":"2024071909335802700_llae010-B30","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/0018726708094863","article-title":"Survey response rate levels and trends in organizational research","volume":"61","author":"Baruch","year":"2008","journal-title":"Hum Relat"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae010\/57242676\/llae010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/810\/58594102\/llae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/810\/58594102\/llae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T09:34:19Z","timestamp":1721381659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/8\/810\/7584710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,1,20]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae010","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,1,20]]}}}